A
A. Bruce Montgomery
Researcher at University of California, San Francisco
Publications - 33
Citations - 3498
A. Bruce Montgomery is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Placebo & Idiopathic pulmonary fibrosis. The author has an hindex of 22, co-authored 32 publications receiving 3172 citations. Previous affiliations of A. Bruce Montgomery include University of North Carolina at Chapel Hill & University of Missouri.
Papers
More filters
Journal ArticleDOI
Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis
Karen McCoy,Alexandra L. Quittner,Christopher M. Oermann,Ronald L. Gibson,George Z. Retsch-Bogart,A. Bruce Montgomery +5 more
TL;DR: AZLI delayed time to need for inhaled or intravenous antipseudomonal antibiotics, improved respiratory symptoms and pulmonary function, and was well tolerated in patients with CF using frequent TIS therapy.
Journal ArticleDOI
Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration
James D. Marks,Cara Marks,John M. Ljuce,A. Bruce Montgomery,Joan Turner,Craig A. Metz,John F. Murray +6 more
TL;DR: Serial plasma samples from 86 patients enrolled in a prospective randomized trial of the effects of methylprednisolone in septic shock were assayed for the presence of cytokine tumor necrosis factor (TNF).
Journal ArticleDOI
Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway Infection
Alexandra L. Quittner,Avani C. Modi,Claire E. Wainwright,Kelly L. Otto,Jean Kirihara,A. Bruce Montgomery +5 more
TL;DR: In this article, the authors used a global rating-of-change questionnaire (GRCQ) to assess patients' perceptions of change in their respiratory symptoms after TIS treatment, and mapped the mean change from baseline CFQ-R-Respiratory scores onto the GRCQ to estimate the minimal clinically important difference (MCID).
Journal ArticleDOI
Effect of Chronic Intermittent Administration of Inhaled Tobramycin on Respiratory Microbial Flora in Patients with Cystic Fibrosis
Jane L. Burns,Jill M. Van Dalfsen,Ribhi M. Shawar,Kelly L. Otto,Richard L. Garber,Joanne M. Quan,A. Bruce Montgomery,Gary M. Albers,Bonnie W. Ramsey,Arnold L. Smith +9 more
TL;DR: Microbiology results from two multicenter, double-blind, placebo-controlled trials of inhaled tobramycin in cystic fibrosis were monitored for longitudinal changes in sputum microbial flora, antibiotic susceptibility, and selection of P. aeruginosa isolates with decreased tobramYcin susceptibility.
Journal ArticleDOI
Defining a pulmonary exacerbation in cystic fibrosis.
Margaret Rosenfeld,Julia Emerson,Judy Williams-Warren,Margaret Pepe,Arnold L. Smith,A. Bruce Montgomery,Bonnie W. Ramsey +6 more
TL;DR: It is hoped that the proposed PEx score might serve as a standardized outcome measure for future clinical trials in cystic fibrosis, allowing meaningful comparisons of study results.